Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
Chapter 3. Research Methodology
3.1. Introduction
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
Chapter 4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
4.4. Challenges
4.5. Macroeconomic Indicators
4.6. Detection Technique Trends & Assessment
Chapter 5. Market Factor Analysis
5.1. Porterโs Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.3. Investment Feasibility Analysis
5.4. Pricing Analysis
Chapter 6. Global Transdermal (Percutaneous) Drug Delivery Systems Market, by Product
6.1. Introduction
6.2. Transdermal Patches
6.2.1. Drug-in-adhesive Patches
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.2.2. Matrix Patches
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.2.3. Reservoir Membrane Patches
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.2.4. Microneedle Patches
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.3. Transdermal Semisolids
6.3.1. Gels
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.3.2. Ointments
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
6.3.3. Sprays
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 7. Global Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology
7.1. Introduction
7.2. Electric Current
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.3. Iontophoresis
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.4. Electroporation
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.5. Ultrasound
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.6. Microporation
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.7. Thermal
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
7.8. Others
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 8. Global Transdermal (Percutaneous) Drug Delivery Systems Market, by Application
8.1. Introduction
8.2. Pain Management
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.3. Cardiovascular Diseases
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.4. Hormone Replacement Therapy
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.5. Central Nervous System Disorders
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.6. Smoking Cessation
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.7. Contraception
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
8.8. Others
Market Estimates & Forecast, by Region, 2023-2030
Market Estimates & Forecast, by Country, 2023-2030
Chapter 9. Global Transdermal (Percutaneous) Drug Delivery Systems Market, by Region
9.1. Introduction
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
Chapter 10. Company Landscape
10.1. Introduction
10.2. Market Share Analysis
10.3. Key Developments & Strategies
Chapter 11. Company Profiles
11.1. Mylan N.V.
11.1.1. Company Overview
11.1.2. Product Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Hisamitsu Pharmaceutical Co., Inc.
11.2.1. Company Overview
11.2.2. Product Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Novartis International AG
11.3.1. Company Overview
11.3.2. Product Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Boehringer Ingelheim International GmbH
11.4.1. Company Overview
11.4.2. Product Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. GlaxoSmithKline Plc
11.5.1. Company Overview
11.5.2. Product Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Johnson & Johnson Services, Inc.
11.6.1. Company Overview
11.6.2. Product Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Endo Pharmaceuticals Inc.
11.7.1. Company Overview
11.7.2. Product Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. UCB S.A.
11.8.1. Company Overview
11.8.2. Product Overview
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Pfizer Inc.
11.9.1. Company Overview
11.9.2. Product Overview
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Allergan plc
11.10.1. Company Overview
11.10.2. Product Overview
11.10.3. Financial Overview
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Actelion Pharmaceuticals Ltd
11.11.1. Company Overview
11.11.2. Product Overview
11.11.3. Financial Overview
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. Noven Pharmaceuticals, Inc.
11.12.1. Company Overview
11.12.2. Product Overview
11.12.3. Financial Overview
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
Chapter 12. MRFR Conclusion
12.1. Key Findings
12.1.1. From CEOโs Viewpoint
12.1.2. Unmet Needs of the Market
12.2. Key Companies to Watch
12.3. Predictions for the Transdermal (Percutaneous) Drug Delivery Systems Industry
Chapter 13. Appendix
LIST OF TABLES
Table 1. Global Transdermal (Percutaneous) Drug Delivery Systems Market Synopsis, 2023-2030
Table 2. Global Transdermal (Percutaneous) Drug Delivery Systems Market Estimates and Forecast, 2023-2030 (USD Million)
Table 3. Global Transdermal (Percutaneous) Drug Delivery Systems Market, by Region, 2023-2030 (USD Million)
Table 4. Global Transdermal (Percutaneous) Drug Delivery Systems Market, by Product, 2023-2030 (USD Million)
Table 5. Global Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology, 2023-2030 (USD Million)
Table 6. Global Transdermal (Percutaneous) Drug Delivery Systems Market, by Application, 2023-2030 (USD Million)
Table 7. North America: Transdermal (Percutaneous) Drug Delivery Systems Market, by Product, 2023-2030 (USD Million)
Table 8. North America: Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology, 2023-2030 (USD Million)
Table 9. North America: Transdermal (Percutaneous) Drug Delivery Systems Market, by Application, 2023-2030 (USD Million)
Table 10. US: Transdermal (Percutaneous) Drug Delivery Systems Market, by Product, 2023-2030 (USD Million)
Table 11. US: Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology, 2023-2030 (USD Million)
Table 12. US: Transdermal (Percutaneous) Drug Delivery Systems Market, by Application, 2023-2030 (USD Million)
Table 13. Canada: Transdermal (Percutaneous) Drug Delivery Systems Market, by Product, 2023-2030 (USD Million)
Table 14. Canada: Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology, 2023-2030 (USD Million)
Table 15. Canada: Transdermal (Percutaneous) Drug Delivery Systems Market, by Application, 2023-2030 (USD Million)
Table 16. Latin America: Transdermal (Percutaneous) Drug Delivery Systems Market, by Product, 2023-2030 (USD Million)
Table 17. Latin America: Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology, 2023-2030 (USD Million)
Table 18. Latin America: Transdermal (Percutaneous) Drug Delivery Systems Market, by Application, 2023-2030 (USD Million)
Table 19. Europe: Transdermal (Percutaneous) Drug Delivery Systems Market, by Product, 2023-2030 (USD Million)
Table 20. Europe: Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology, 2023-2030 (USD Million)
Table 21. Europe: Transdermal (Percutaneous) Drug Delivery Systems Market, by Application, 2023-2030 (USD Million)
Table 22. Western Europe: Transdermal (Percutaneous) Drug Delivery Systems Market, by Product, 2023-2030 (USD Million)
Table 23. Western Europe: Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology, 2023-2030 (USD Million)
Table 24. Western Europe: Transdermal (Percutaneous) Drug Delivery Systems Market, by Application, 2023-2030 (USD Million)
Table 25. Eastern Europe: Transdermal (Percutaneous) Drug Delivery Systems Market, by Product, 2023-2030 (USD Million)
Table 26. Eastern Europe: Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology, 2023-2030 (USD Million)
Table 27. Eastern Europe: Transdermal (Percutaneous) Drug Delivery Systems Market, by Application, 2023-2030 (USD Million)
Table 28. Asia-Pacific: Transdermal (Percutaneous) Drug Delivery Systems Market, by Product, 2023-2030 (USD Million)
Table 29. Asia-Pacific: Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology, 2023-2030 (USD Million)
Table 30. Asia-Pacific: Transdermal (Percutaneous) Drug Delivery Systems Market, by Application, 2023-2030 (USD Million)
Table 31. Middle East & Africa: Transdermal (Percutaneous) Drug Delivery Systems Market, by Product, 2023-2030 (USD Million)
Table 32. Middle East & Africa: Transdermal (Percutaneous) Drug Delivery Systems Market, by Technology, 2023-2030 (USD Million)
Table 33. Middle East & Africa: Transdermal (Percutaneous) Drug Delivery Systems Market, by Application, 2023-2030 (USD Million)
LIST OF FIGURES
Figure 1. Research Process
Figure 2. Segmentation for Global Transdermal (Percutaneous) Drug Delivery Systems Market
Figure 3. Segmentation Market Dynamics for Global Transdermal (Percutaneous) Drug Delivery Systems Market
Figure 4. Global Transdermal (Percutaneous) Drug Delivery Systems Market Share, by Product, 2020
Figure 5. Global Transdermal (Percutaneous) Drug Delivery Systems Market Share, by Technology, 2020
Figure 6. Global Transdermal (Percutaneous) Drug Delivery Systems Market Share, by Application, 2020
Figure 7. Global Transdermal (Percutaneous) Drug Delivery Systems Market Share, by Region, 2020
Figure 8. North America: Transdermal (Percutaneous) Drug Delivery Systems Market Share, by Country, 2020
Figure 9. Europe: Transdermal (Percutaneous) Drug Delivery Systems Market Share, by Country, 2020
Figure 10. Asia-Pacific: Transdermal (Percutaneous) Drug Delivery Systems Market Share, by Country, 2020
Figure 11. Middle East & Africa: Transdermal (Percutaneous) Drug Delivery Systems Market Share, by Country, 2020
Figure 12. Global Transdermal (Percutaneous) Drug Delivery Systems Market: Company Share Analysis, 2020 (%)
Figure 13. Mylan N.V.: Key Financials
Figure 14. Mylan N.V.: Segmental Revenue
Figure 15. Mylan N.V.: Geographical Revenue
Figure 16. Hisamitsu Pharmaceutical Co., Inc.: Key Financials
Figure 17. Hisamitsu Pharmaceutical Co., Inc.: Segmental Revenue
Figure 18. Hisamitsu Pharmaceutical Co., Inc.: Geographical Revenue
Figure 19. Novartis International AG: Key Financials
Figure 20. Novartis International AG: Segmental Revenue
Figure 21. Novartis International AG: Geographical Revenue
Figure 22. Boehringer Ingelheim International GmbH: Key Financials
Figure 23. Boehringer Ingelheim International GmbH: Segmental Revenue
Figure 24. Boehringer Ingelheim International GmbH: Geographical Revenue
Figure 25. GlaxoSmithKline plc: Key Financials
Figure 26. GlaxoSmithKline plc: Segmental Revenue
Figure 27. GlaxoSmithKline plc: Geographical Revenue
Figure 28. Johnson & Johnson Services, Inc.: Key Financials
Figure 29. Johnson & Johnson Services, Inc.: Segmental Revenue
Figure 30. Johnson & Johnson Services, Inc.: Geographical Revenue
Figure 31. Endo Pharmaceuticals Inc.: Key Financials
Figure 32. Endo Pharmaceuticals Inc.: Segmental Revenue
Figure 33. Endo Pharmaceuticals Inc.: Geographical Revenue
Figure 34. UCB S.A.: Key Financials
Figure 35. UCB S.A.: Segmental Revenue
Figure 36. UCB S.A.: Geographical Revenue
Figure 37. Pfizer Inc.: Key Financials
Figure 38. Pfizer Inc.: Segmental Revenue
Figure 39. Pfizer Inc.: Geographical Revenue
Figure 40. Allergan plc: Key Financials
Figure 41. Allergan plc: Segmental Revenue
Figure 42. Allergan plc: Geographical Revenue
Figure 43. Actelion Pharmaceuticals Ltd: Key Financials
Figure 44. Actelion Pharmaceuticals Ltd: Segmental Revenue
Figure 45. Actelion Pharmaceuticals Ltd: Geographical Revenue
Figure 46. Noven Pharmaceuticals, Inc.: Key Financials
Figure 47. Noven Pharmaceuticals, Inc.: Segmental Revenue
Figure 48. Noven Pharmaceuticals, Inc.: Geographical Revenue